☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
NTRK
Foundation Medicine's FoundationOne CDx Receives the US FDA's Approval as a CDx for Vitrakvi (larotrectinib)
October 26, 2020
Roche's Rozlytrek (entrectinib) Receives the US FDA Approval for ROS1-Positive Metastatic Non-Small Cell Lung Cancer and NTRK Gene...
August 16, 2019
Roche's Polatuzumab Vedotin as Combination Therapy & Entrectinib Receives FDA's Priority Review for r/r Diffuse DLBCL & NT...
February 19, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.